Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cogent Biosciences, Inc.COGT · Entity 3793 | Director | October 01, 2026 | October 05, 2026 |
| MACROGENICS INCMGNX · Entity 6104 | Director | May 18, 2026 | May 20, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cogent Biosciences, Inc.
Report date October 01, 2026 · Filed October 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $31.59 · Expires 2036-10-01 | Direct | 759 |
Reported balance
After 2026-10-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-10-01 · Grant · Acquired 759 · Balance 759 F1: The option award was issued to the Reporting Person, who elected to take shares in lieu of cash compensation for services as a director, pursuant to the Issuer's non-employee director compensation plan. The number of options granted was determined by dividing the cash compensation otherwise payable with respect to the quarter by the Black-Scholes value of a single option calculated as of the date of the grant. |
Filing footnotes · ownership attribution and instrument terms
F1: The option award was issued to the Reporting Person, who elected to take shares in lieu of cash compensation for services as a director, pursuant to the Issuer's non-employee director compensation plan. The number of options granted was determined by dividing the cash compensation otherwise payable with respect to the quarter by the Black-Scholes value of a single option calculated as of the date of the grant.
MACROGENICS INC
Report date May 18, 2026 · Filed May 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 14,750 |
Reported balance
After 2026-05-18 transaction · row 1
1 source rowRow 1 · 2026-05-18 · Exercise / conversion · Acquired 3,750 · Balance 14,750 F1: Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's common stock. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2026-05-18 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-05-18 · Exercise / conversion · Disposed 3,750 · Balance 0 F1: Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's common stock. F2: The RSUs vested on May 18, 2026, which was one day prior to the Issuer's 2026 Annual Meeting of Stockholders held on May 19, 2026. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 3,750 |
Reported balance
After 2026-05-19 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-05-19 · Grant · Acquired 3,750 · Balance 3,750 F1: Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's common stock. F3: The RSUs will vest one year after the date of grant, or the day prior to the next annual meeting, if earlier |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.52 · Expires 2036-05-19 | Direct | 22,000 |
Reported balance
After 2026-05-19 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-05-19 · Grant · Acquired 22,000 · Balance 22,000 F4: The option will vest and become exercisable in monthly, cumulative 1/12th increments (rounded upwards for whole shares) beginning one month from the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's common stock.
F2: The RSUs vested on May 18, 2026, which was one day prior to the Issuer's 2026 Annual Meeting of Stockholders held on May 19, 2026.
F3: The RSUs will vest one year after the date of grant, or the day prior to the next annual meeting, if earlier
F4: The option will vest and become exercisable in monthly, cumulative 1/12th increments (rounded upwards for whole shares) beginning one month from the date of grant.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
PROGENICS PHARMACEUTICALS INC
Report date June 19, 2020 · Filed June 23, 2020
Section 16 reporting ended · disclosed 2020-06-23. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.50 · Expires 2024-01-28 | Direct | 0 |
Reported balance
After 2020-06-19 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-06-19 · Disposition to issuer · Disposed 40,000 · Balance 0 F1: On June 19, 2020, pursuant to the Amended and Restated Agreement and Plan of Merger, dated February 20, 2020 (the "Merger Agreement") among Lantheus Holdings, Inc. ("Lantheus"), Plato Merger Sub, Inc., a wholly-owned subsidiary of Lantheus ("Merger Sub"), and Progenics Pharmaceuticals, Inc. ("Progenics"), Merger Sub merged with and into Progenics (the "Merger"), with Progenics surviving as a wholly-owned subsidiary of Lantheus. At the effective time of the Merger, this option was assumed by Lantheus and converted into an option to purchase Lantheus common stock based on an exchange ratio of 0.31 of a share of Lantheus common stock for each share of Progenics common stock subject to the option (with a corresponding adjustment being made to the exercise price of the option). Except for these adjustments, the other terms of the option continue in effect. Each of these options is fully vested and exercisable. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.47 · Expires 2024-06-16 | Direct | 0 |
Reported balance
After 2020-06-19 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-06-19 · Disposition to issuer · Disposed 20,000 · Balance 0 F1: On June 19, 2020, pursuant to the Amended and Restated Agreement and Plan of Merger, dated February 20, 2020 (the "Merger Agreement") among Lantheus Holdings, Inc. ("Lantheus"), Plato Merger Sub, Inc., a wholly-owned subsidiary of Lantheus ("Merger Sub"), and Progenics Pharmaceuticals, Inc. ("Progenics"), Merger Sub merged with and into Progenics (the "Merger"), with Progenics surviving as a wholly-owned subsidiary of Lantheus. At the effective time of the Merger, this option was assumed by Lantheus and converted into an option to purchase Lantheus common stock based on an exchange ratio of 0.31 of a share of Lantheus common stock for each share of Progenics common stock subject to the option (with a corresponding adjustment being made to the exercise price of the option). Except for these adjustments, the other terms of the option continue in effect. Each of these options is fully vested and exercisable. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.72 · Expires 2025-06-09 | Direct | 0 |
Reported balance
After 2020-06-19 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-06-19 · Disposition to issuer · Disposed 20,000 · Balance 0 F1: On June 19, 2020, pursuant to the Amended and Restated Agreement and Plan of Merger, dated February 20, 2020 (the "Merger Agreement") among Lantheus Holdings, Inc. ("Lantheus"), Plato Merger Sub, Inc., a wholly-owned subsidiary of Lantheus ("Merger Sub"), and Progenics Pharmaceuticals, Inc. ("Progenics"), Merger Sub merged with and into Progenics (the "Merger"), with Progenics surviving as a wholly-owned subsidiary of Lantheus. At the effective time of the Merger, this option was assumed by Lantheus and converted into an option to purchase Lantheus common stock based on an exchange ratio of 0.31 of a share of Lantheus common stock for each share of Progenics common stock subject to the option (with a corresponding adjustment being made to the exercise price of the option). Except for these adjustments, the other terms of the option continue in effect. Each of these options is fully vested and exercisable. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.89 · Expires 2026-06-07 | Direct | 0 |
Reported balance
After 2020-06-19 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2020-06-19 · Disposition to issuer · Disposed 20,000 · Balance 0 F1: On June 19, 2020, pursuant to the Amended and Restated Agreement and Plan of Merger, dated February 20, 2020 (the "Merger Agreement") among Lantheus Holdings, Inc. ("Lantheus"), Plato Merger Sub, Inc., a wholly-owned subsidiary of Lantheus ("Merger Sub"), and Progenics Pharmaceuticals, Inc. ("Progenics"), Merger Sub merged with and into Progenics (the "Merger"), with Progenics surviving as a wholly-owned subsidiary of Lantheus. At the effective time of the Merger, this option was assumed by Lantheus and converted into an option to purchase Lantheus common stock based on an exchange ratio of 0.31 of a share of Lantheus common stock for each share of Progenics common stock subject to the option (with a corresponding adjustment being made to the exercise price of the option). Except for these adjustments, the other terms of the option continue in effect. Each of these options is fully vested and exercisable. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.95 · Expires 2027-06-13 | Direct | 0 |
Reported balance
After 2020-06-19 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2020-06-19 · Disposition to issuer · Disposed 20,000 · Balance 0 F1: On June 19, 2020, pursuant to the Amended and Restated Agreement and Plan of Merger, dated February 20, 2020 (the "Merger Agreement") among Lantheus Holdings, Inc. ("Lantheus"), Plato Merger Sub, Inc., a wholly-owned subsidiary of Lantheus ("Merger Sub"), and Progenics Pharmaceuticals, Inc. ("Progenics"), Merger Sub merged with and into Progenics (the "Merger"), with Progenics surviving as a wholly-owned subsidiary of Lantheus. At the effective time of the Merger, this option was assumed by Lantheus and converted into an option to purchase Lantheus common stock based on an exchange ratio of 0.31 of a share of Lantheus common stock for each share of Progenics common stock subject to the option (with a corresponding adjustment being made to the exercise price of the option). Except for these adjustments, the other terms of the option continue in effect. Each of these options is fully vested and exercisable. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.99 · Expires 2028-06-12 | Direct | 0 |
Reported balance
After 2020-06-19 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2020-06-19 · Disposition to issuer · Disposed 25,000 · Balance 0 F1: On June 19, 2020, pursuant to the Amended and Restated Agreement and Plan of Merger, dated February 20, 2020 (the "Merger Agreement") among Lantheus Holdings, Inc. ("Lantheus"), Plato Merger Sub, Inc., a wholly-owned subsidiary of Lantheus ("Merger Sub"), and Progenics Pharmaceuticals, Inc. ("Progenics"), Merger Sub merged with and into Progenics (the "Merger"), with Progenics surviving as a wholly-owned subsidiary of Lantheus. At the effective time of the Merger, this option was assumed by Lantheus and converted into an option to purchase Lantheus common stock based on an exchange ratio of 0.31 of a share of Lantheus common stock for each share of Progenics common stock subject to the option (with a corresponding adjustment being made to the exercise price of the option). Except for these adjustments, the other terms of the option continue in effect. Each of these options is fully vested and exercisable. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.74 · Expires 2029-07-11 | Direct | 0 |
Reported balance
After 2020-06-19 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2020-06-19 · Disposition to issuer · Disposed 25,000 · Balance 0 F1: On June 19, 2020, pursuant to the Amended and Restated Agreement and Plan of Merger, dated February 20, 2020 (the "Merger Agreement") among Lantheus Holdings, Inc. ("Lantheus"), Plato Merger Sub, Inc., a wholly-owned subsidiary of Lantheus ("Merger Sub"), and Progenics Pharmaceuticals, Inc. ("Progenics"), Merger Sub merged with and into Progenics (the "Merger"), with Progenics surviving as a wholly-owned subsidiary of Lantheus. At the effective time of the Merger, this option was assumed by Lantheus and converted into an option to purchase Lantheus common stock based on an exchange ratio of 0.31 of a share of Lantheus common stock for each share of Progenics common stock subject to the option (with a corresponding adjustment being made to the exercise price of the option). Except for these adjustments, the other terms of the option continue in effect. Each of these options is fully vested and exercisable. |
Filing footnotes · ownership attribution and instrument terms
F1: On June 19, 2020, pursuant to the Amended and Restated Agreement and Plan of Merger, dated February 20, 2020 (the "Merger Agreement") among Lantheus Holdings, Inc. ("Lantheus"), Plato Merger Sub, Inc., a wholly-owned subsidiary of Lantheus ("Merger Sub"), and Progenics Pharmaceuticals, Inc. ("Progenics"), Merger Sub merged with and into Progenics (the "Merger"), with Progenics surviving as a wholly-owned subsidiary of Lantheus. At the effective time of the Merger, this option was assumed by Lantheus and converted into an option to purchase Lantheus common stock based on an exchange ratio of 0.31 of a share of Lantheus common stock for each share of Progenics common stock subject to the option (with a corresponding adjustment being made to the exercise price of the option). Except for these adjustments, the other terms of the option continue in effect. Each of these options is fully vested and exercisable.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 19, 2020 Filed Jun 23, 2020 16:47 UTC | PROGENICS PHARMACEUTICALS INC PGNX · Entity 148291 | Disposition to issuerStock Option (Right to Buy) · Derivative | 25,000 | Not disclosed Strike: $8.99 | Not disclosed |
DisclosureSEC source: 0001437749-20-013673 · rdgdoc.xml · derivative · entry 6 Ferrante Karen Jean · CIK 0001598502 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires 2028-06-12 F1 · price: On June 19, 2020, pursuant to the Amended and Restated Agreement and Plan of Merger, dated February 20, 2020 (the "Merger Agreement") among Lantheus Holdings, Inc. ("Lantheus"), Plato Merger Sub, Inc., a wholly-owned subsidiary of Lantheus ("Merger Sub"), and Progenics Pharmaceuticals, Inc. ("Progenics"), Merger Sub merged with and into Progenics (the "Merger"), with Progenics surviving as a wholly-owned subsidiary of Lantheus. At the effective time of the Merger, this option was assumed by Lantheus and converted into an option to purchase Lantheus common stock based on an exchange ratio of 0.31 of a share of Lantheus common stock for each share of Progenics common stock subject to the option (with a corresponding adjustment being made to the exercise price of the option). Except for these adjustments, the other terms of the option continue in effect. Each of these options is fully vested and exercisable. F1 · derivative.exercise_date: On June 19, 2020, pursuant to the Amended and Restated Agreement and Plan of Merger, dated February 20, 2020 (the "Merger Agreement") among Lantheus Holdings, Inc. ("Lantheus"), Plato Merger Sub, Inc., a wholly-owned subsidiary of Lantheus ("Merger Sub"), and Progenics Pharmaceuticals, Inc. ("Progenics"), Merger Sub merged with and into Progenics (the "Merger"), with Progenics surviving as a wholly-owned subsidiary of Lantheus. At the effective time of the Merger, this option was assumed by Lantheus and converted into an option to purchase Lantheus common stock based on an exchange ratio of 0.31 of a share of Lantheus common stock for each share of Progenics common stock subject to the option (with a corresponding adjustment being made to the exercise price of the option). Except for these adjustments, the other terms of the option continue in effect. Each of these options is fully vested and exercisable. Read SEC document |
| June 19, 2020 Filed Jun 23, 2020 16:47 UTC | PROGENICS PHARMACEUTICALS INC PGNX · Entity 148291 | Disposition to issuerStock Option (Right to Buy) · Derivative | 20,000 | Not disclosed Strike: $6.95 | Not disclosed |
DisclosureSEC source: 0001437749-20-013673 · rdgdoc.xml · derivative · entry 5 Ferrante Karen Jean · CIK 0001598502 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2027-06-13 F1 · price: On June 19, 2020, pursuant to the Amended and Restated Agreement and Plan of Merger, dated February 20, 2020 (the "Merger Agreement") among Lantheus Holdings, Inc. ("Lantheus"), Plato Merger Sub, Inc., a wholly-owned subsidiary of Lantheus ("Merger Sub"), and Progenics Pharmaceuticals, Inc. ("Progenics"), Merger Sub merged with and into Progenics (the "Merger"), with Progenics surviving as a wholly-owned subsidiary of Lantheus. At the effective time of the Merger, this option was assumed by Lantheus and converted into an option to purchase Lantheus common stock based on an exchange ratio of 0.31 of a share of Lantheus common stock for each share of Progenics common stock subject to the option (with a corresponding adjustment being made to the exercise price of the option). Except for these adjustments, the other terms of the option continue in effect. Each of these options is fully vested and exercisable. F1 · derivative.exercise_date: On June 19, 2020, pursuant to the Amended and Restated Agreement and Plan of Merger, dated February 20, 2020 (the "Merger Agreement") among Lantheus Holdings, Inc. ("Lantheus"), Plato Merger Sub, Inc., a wholly-owned subsidiary of Lantheus ("Merger Sub"), and Progenics Pharmaceuticals, Inc. ("Progenics"), Merger Sub merged with and into Progenics (the "Merger"), with Progenics surviving as a wholly-owned subsidiary of Lantheus. At the effective time of the Merger, this option was assumed by Lantheus and converted into an option to purchase Lantheus common stock based on an exchange ratio of 0.31 of a share of Lantheus common stock for each share of Progenics common stock subject to the option (with a corresponding adjustment being made to the exercise price of the option). Except for these adjustments, the other terms of the option continue in effect. Each of these options is fully vested and exercisable. Read SEC document |
| June 19, 2020 Filed Jun 23, 2020 16:47 UTC | PROGENICS PHARMACEUTICALS INC PGNX · Entity 148291 | Disposition to issuerStock Option (Right to Buy) · Derivative | 20,000 | Not disclosed Strike: $4.89 | Not disclosed |
DisclosureSEC source: 0001437749-20-013673 · rdgdoc.xml · derivative · entry 4 Ferrante Karen Jean · CIK 0001598502 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2026-06-07 F1 · price: On June 19, 2020, pursuant to the Amended and Restated Agreement and Plan of Merger, dated February 20, 2020 (the "Merger Agreement") among Lantheus Holdings, Inc. ("Lantheus"), Plato Merger Sub, Inc., a wholly-owned subsidiary of Lantheus ("Merger Sub"), and Progenics Pharmaceuticals, Inc. ("Progenics"), Merger Sub merged with and into Progenics (the "Merger"), with Progenics surviving as a wholly-owned subsidiary of Lantheus. At the effective time of the Merger, this option was assumed by Lantheus and converted into an option to purchase Lantheus common stock based on an exchange ratio of 0.31 of a share of Lantheus common stock for each share of Progenics common stock subject to the option (with a corresponding adjustment being made to the exercise price of the option). Except for these adjustments, the other terms of the option continue in effect. Each of these options is fully vested and exercisable. F1 · derivative.exercise_date: On June 19, 2020, pursuant to the Amended and Restated Agreement and Plan of Merger, dated February 20, 2020 (the "Merger Agreement") among Lantheus Holdings, Inc. ("Lantheus"), Plato Merger Sub, Inc., a wholly-owned subsidiary of Lantheus ("Merger Sub"), and Progenics Pharmaceuticals, Inc. ("Progenics"), Merger Sub merged with and into Progenics (the "Merger"), with Progenics surviving as a wholly-owned subsidiary of Lantheus. At the effective time of the Merger, this option was assumed by Lantheus and converted into an option to purchase Lantheus common stock based on an exchange ratio of 0.31 of a share of Lantheus common stock for each share of Progenics common stock subject to the option (with a corresponding adjustment being made to the exercise price of the option). Except for these adjustments, the other terms of the option continue in effect. Each of these options is fully vested and exercisable. Read SEC document |
| June 19, 2020 Filed Jun 23, 2020 16:47 UTC | PROGENICS PHARMACEUTICALS INC PGNX · Entity 148291 | Disposition to issuerStock Option (Right to Buy) · Derivative | 20,000 | Not disclosed Strike: $6.72 | Not disclosed |
DisclosureSEC source: 0001437749-20-013673 · rdgdoc.xml · derivative · entry 3 Ferrante Karen Jean · CIK 0001598502 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2025-06-09 F1 · price: On June 19, 2020, pursuant to the Amended and Restated Agreement and Plan of Merger, dated February 20, 2020 (the "Merger Agreement") among Lantheus Holdings, Inc. ("Lantheus"), Plato Merger Sub, Inc., a wholly-owned subsidiary of Lantheus ("Merger Sub"), and Progenics Pharmaceuticals, Inc. ("Progenics"), Merger Sub merged with and into Progenics (the "Merger"), with Progenics surviving as a wholly-owned subsidiary of Lantheus. At the effective time of the Merger, this option was assumed by Lantheus and converted into an option to purchase Lantheus common stock based on an exchange ratio of 0.31 of a share of Lantheus common stock for each share of Progenics common stock subject to the option (with a corresponding adjustment being made to the exercise price of the option). Except for these adjustments, the other terms of the option continue in effect. Each of these options is fully vested and exercisable. F1 · derivative.exercise_date: On June 19, 2020, pursuant to the Amended and Restated Agreement and Plan of Merger, dated February 20, 2020 (the "Merger Agreement") among Lantheus Holdings, Inc. ("Lantheus"), Plato Merger Sub, Inc., a wholly-owned subsidiary of Lantheus ("Merger Sub"), and Progenics Pharmaceuticals, Inc. ("Progenics"), Merger Sub merged with and into Progenics (the "Merger"), with Progenics surviving as a wholly-owned subsidiary of Lantheus. At the effective time of the Merger, this option was assumed by Lantheus and converted into an option to purchase Lantheus common stock based on an exchange ratio of 0.31 of a share of Lantheus common stock for each share of Progenics common stock subject to the option (with a corresponding adjustment being made to the exercise price of the option). Except for these adjustments, the other terms of the option continue in effect. Each of these options is fully vested and exercisable. Read SEC document |
| June 19, 2020 Filed Jun 23, 2020 16:47 UTC | PROGENICS PHARMACEUTICALS INC PGNX · Entity 148291 | Disposition to issuerStock Option (Right to Buy) · Derivative | 20,000 | Not disclosed Strike: $4.47 | Not disclosed |
DisclosureSEC source: 0001437749-20-013673 · rdgdoc.xml · derivative · entry 2 Ferrante Karen Jean · CIK 0001598502 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2024-06-16 F1 · price: On June 19, 2020, pursuant to the Amended and Restated Agreement and Plan of Merger, dated February 20, 2020 (the "Merger Agreement") among Lantheus Holdings, Inc. ("Lantheus"), Plato Merger Sub, Inc., a wholly-owned subsidiary of Lantheus ("Merger Sub"), and Progenics Pharmaceuticals, Inc. ("Progenics"), Merger Sub merged with and into Progenics (the "Merger"), with Progenics surviving as a wholly-owned subsidiary of Lantheus. At the effective time of the Merger, this option was assumed by Lantheus and converted into an option to purchase Lantheus common stock based on an exchange ratio of 0.31 of a share of Lantheus common stock for each share of Progenics common stock subject to the option (with a corresponding adjustment being made to the exercise price of the option). Except for these adjustments, the other terms of the option continue in effect. Each of these options is fully vested and exercisable. F1 · derivative.exercise_date: On June 19, 2020, pursuant to the Amended and Restated Agreement and Plan of Merger, dated February 20, 2020 (the "Merger Agreement") among Lantheus Holdings, Inc. ("Lantheus"), Plato Merger Sub, Inc., a wholly-owned subsidiary of Lantheus ("Merger Sub"), and Progenics Pharmaceuticals, Inc. ("Progenics"), Merger Sub merged with and into Progenics (the "Merger"), with Progenics surviving as a wholly-owned subsidiary of Lantheus. At the effective time of the Merger, this option was assumed by Lantheus and converted into an option to purchase Lantheus common stock based on an exchange ratio of 0.31 of a share of Lantheus common stock for each share of Progenics common stock subject to the option (with a corresponding adjustment being made to the exercise price of the option). Except for these adjustments, the other terms of the option continue in effect. Each of these options is fully vested and exercisable. Read SEC document |
| June 19, 2020 Filed Jun 23, 2020 16:47 UTC | PROGENICS PHARMACEUTICALS INC PGNX · Entity 148291 | Disposition to issuerStock Option (Right to Buy) · Derivative | 40,000 | Not disclosed Strike: $4.50 | Not disclosed |
DisclosureSEC source: 0001437749-20-013673 · rdgdoc.xml · derivative · entry 1 Ferrante Karen Jean · CIK 0001598502 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 40,000 shares Expires 2024-01-28 F1 · price: On June 19, 2020, pursuant to the Amended and Restated Agreement and Plan of Merger, dated February 20, 2020 (the "Merger Agreement") among Lantheus Holdings, Inc. ("Lantheus"), Plato Merger Sub, Inc., a wholly-owned subsidiary of Lantheus ("Merger Sub"), and Progenics Pharmaceuticals, Inc. ("Progenics"), Merger Sub merged with and into Progenics (the "Merger"), with Progenics surviving as a wholly-owned subsidiary of Lantheus. At the effective time of the Merger, this option was assumed by Lantheus and converted into an option to purchase Lantheus common stock based on an exchange ratio of 0.31 of a share of Lantheus common stock for each share of Progenics common stock subject to the option (with a corresponding adjustment being made to the exercise price of the option). Except for these adjustments, the other terms of the option continue in effect. Each of these options is fully vested and exercisable. F1 · derivative.exercise_date: On June 19, 2020, pursuant to the Amended and Restated Agreement and Plan of Merger, dated February 20, 2020 (the "Merger Agreement") among Lantheus Holdings, Inc. ("Lantheus"), Plato Merger Sub, Inc., a wholly-owned subsidiary of Lantheus ("Merger Sub"), and Progenics Pharmaceuticals, Inc. ("Progenics"), Merger Sub merged with and into Progenics (the "Merger"), with Progenics surviving as a wholly-owned subsidiary of Lantheus. At the effective time of the Merger, this option was assumed by Lantheus and converted into an option to purchase Lantheus common stock based on an exchange ratio of 0.31 of a share of Lantheus common stock for each share of Progenics common stock subject to the option (with a corresponding adjustment being made to the exercise price of the option). Except for these adjustments, the other terms of the option continue in effect. Each of these options is fully vested and exercisable. Read SEC document |
| June 09, 2020 Filed Jun 11, 2020 20:24 UTC | Cogent Biosciences, Inc. UMRX · Entity 3793 | GrantStock Option (Right to Buy) · Derivative | 14,331 | $0.00 Strike: $0.63 | $0.00 |
DisclosureSEC source: 0001209191-20-035926 · doc4.xml · derivative · entry 1 Ferrante Karen Jean · CIK 0001598502 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,331 Underlying: Common Stock · 14,331 shares Expires 2030-06-09 F1 · derivative.exercise_date: This option shall vest in full on the earlier of (i) June 9, 2021, and (ii) the next annual meeting of the Issuer's stockholders. Read SEC document |
| May 14, 2020 Filed May 15, 2020 20:36 UTC | MACROGENICS INC MGNX · Entity 6104 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $24.97 | $0.00 |
DisclosureSEC source: 0001125345-20-000088 · wf-form4_158957496520267.xml · derivative · entry 1 Ferrante Karen Jean · CIK 0001598502 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2030-05-14 F1 · derivative.exercise_date: The option will vest and become exercisable in monthly, cumulative 1/12th increments (rounded upwards to whole shares) beginning one month from the date of grant. Read SEC document |
| April 06, 2020 Filed Apr 8, 2020 21:41 UTC | Cogent Biosciences, Inc. UMRX · Entity 3793 | GrantStock Option (Right to Buy) · Derivative | 54,422 | $0.22 Strike: $0.35 | $12,000.05 |
DisclosureSEC source: 0001209191-20-023945 · doc4.xml · derivative · entry 1 Ferrante Karen Jean · CIK 0001598502 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,422 Underlying: Common Stock · 54,422 shares Expires 2030-04-06 F1 · shares: The option award was issued to the Reporting Person, who elected to take shares in lieu of cash compensation for services as a director, pursuant to the Issuer's non-employee director compensation plan. The number of options granted was determined by dividing the cash compensation otherwise payable with respect to the quarter by the Black-Scholes value of a single option calculated as of the date of the grant. F2 · derivative.exercise_date: This option is fully vested at time of grant. Read SEC document |
| January 02, 2020 Filed Jan 6, 2020 21:45 UTC | Cogent Biosciences, Inc. UMRX · Entity 3793 | GrantStock Option (Right to Buy) · Derivative | 26,480 | $0.45 Strike: $0.72 | $12,000.74 |
DisclosureSEC source: 0001209191-20-001889 · doc4.xml · derivative · entry 1 Ferrante Karen Jean · CIK 0001598502 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,480 Underlying: Common Stock · 26,480 shares Expires 2030-01-02 F1 · shares: The option award was issued to the Reporting Person, who elected to take shares in lieu of cash compensation for services as a director, pursuant to the Issuer's non-employee director compensation plan. The number of options granted was determined by dividing the cash compensation otherwise payable with respect to the quarter by the Black-Scholes value of a single option calculated as of the date of the grant. F2 · derivative.exercise_date: This option is fully vested at time of grant. Read SEC document |
| October 01, 2019 Filed Oct 3, 2019 20:41 UTC | Cogent Biosciences, Inc. UMRX · Entity 3793 | GrantStock Option (Right to Buy) · Derivative | 13,646 | $0.88 Strike: $1.41 | $12,000.29 |
DisclosureSEC source: 0001209191-19-052261 · doc4.xml · derivative · entry 1 Ferrante Karen Jean · CIK 0001598502 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,646 Underlying: Common Stock · 13,646 shares Expires 2029-10-01 F1 · shares: The option award was issued to the Reporting Person, who elected to take shares in lieu of cash compensation for services as a director, pursuant to the Issuer's non-employee director compensation plan. The number of options granted was determined by dividing the cash compensation otherwise payable with respect to the quarter by the Black-Scholes value of a single option calculated as of the date of the grant. F2 · derivative.exercise_date: This option is fully vested at time of grant. Read SEC document |
| July 11, 2019 Filed Jul 15, 2019 09:01 UTC | PROGENICS PHARMACEUTICALS INC PGNX · Entity 148291 | GrantNon-Qualified Stock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $5.74 | $0.00 |
DisclosureSEC source: 0001562180-19-003933 · primarydocument.xml · derivative · entry 1 Ferrante Karen Jean · CIK 0001598502 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2029-07-11 F1 · derivative.exercise_date: The stock options become exercisable in 12 monthly installments, commencing one month from the grant date. Read SEC document |
| July 01, 2019 Filed Jul 3, 2019 20:06 UTC | Cogent Biosciences, Inc. UMRX · Entity 3793 | GrantStock Option (Right to Buy) · Derivative | 6,199 | $1.77 Strike: $2.41 | $11,000.13 |
DisclosureSEC source: 0001209191-19-041043 · doc4.xml · derivative · entry 1 Ferrante Karen Jean · CIK 0001598502 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,199 Underlying: Common Stock · 6,199 shares Expires 2029-07-01 F1 · shares: The option award was issued to the Reporting Person, who elected to take shares in lieu of cash compensation for services as a director, pursuant to the Issuer's non-employee director compensation plan. The number of options granted was determined by dividing the cash compensation otherwise payable with respect to the quarter by the Black-Scholes value of a single option calculated as of the date of the grant. F2 · derivative.exercise_date: This option is fully vested at time of grant. Read SEC document |
| June 18, 2019 Filed Jun 20, 2019 20:17 UTC | Cogent Biosciences, Inc. UMRX · Entity 3793 | GrantStock Option (Right to Buy) · Derivative | 14,331 | $0.00 Strike: $2.70 | $0.00 |
DisclosureSEC source: 0001209191-19-038220 · doc4.xml · derivative · entry 1 Ferrante Karen Jean · CIK 0001598502 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,331 Underlying: Common Stock · 14,331 shares Expires 2029-06-18 F1 · derivative.exercise_date: This option shall vest in full on the earlier of (i) June 18, 2020, and (ii) the next annual meeting of the Issuer's stockholders. Read SEC document |
| May 16, 2019 Filed May 20, 2019 21:50 UTC | MACROGENICS INC MGNX · Entity 6104 | GrantStock Option (right to buy) · Derivative | 4,616 | $0.00 Strike: $18.00 | $0.00 |
DisclosureSEC source: 0001125345-19-000078 · wf-form4_155838899552570.xml · derivative · entry 2 Ferrante Karen Jean · CIK 0001598502 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,616 Underlying: Common Stock · 4,616 shares Expires 2029-05-16 F1 · derivative.exercise_date: The option will vest and become exercisable in monthly, cumulative 1/12th increments (rounded upwards for whole shares) beginning one month from the date of grant. F2 · derivative.underlying_shares: At the election of the filing person, the option grant is issued in lieu of direct cash compensation of such person's annual retainer through the Company's non-employee director compensation program and will vest and become exercisable in monthly, cumulative 1/12th increments (rounded upwards to whole shares) beginning one month from the date of grant. Read SEC document |
| May 16, 2019 Filed May 20, 2019 21:50 UTC | MACROGENICS INC MGNX · Entity 6104 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $18.00 | $0.00 |
DisclosureSEC source: 0001125345-19-000078 · wf-form4_155838899552570.xml · derivative · entry 1 Ferrante Karen Jean · CIK 0001598502 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2029-05-16 F1 · derivative.exercise_date: The option will vest and become exercisable in monthly, cumulative 1/12th increments (rounded upwards for whole shares) beginning one month from the date of grant. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 20:26 UTC | Cogent Biosciences, Inc. UMRX · Entity 3793 | GrantStock Option (Right to Buy) · Derivative | 4,047 | $2.72 Strike: $4.40 | $11,001.77 |
DisclosureSEC source: 0001209191-19-023125 · doc4.xml · derivative · entry 1 Ferrante Karen Jean · CIK 0001598502 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,047 Underlying: Common Stock · 4,047 shares Expires 2029-04-01 F1 · shares: The option award was issued to the Reporting Person, who elected to take shares in lieu of cash compensation for services as a director, pursuant to the Issuer's non-employee director compensation plan. The number of options granted was determined by dividing the cash compensation otherwise payable with respect to the quarter by the Black-Scholes value of a single option calculated as of the date of the grant. F2 · derivative.exercise_date: This option is fully vested at time of grant. Read SEC document |
| January 02, 2019 Filed Jan 4, 2019 21:54 UTC | Cogent Biosciences, Inc. UMRX · Entity 3793 | GrantStock Option (Right to Buy) · Derivative | 4,073 | $2.70 Strike: $4.47 | $10,997.10 |
DisclosureSEC source: 0001209191-19-002042 · doc4.xml · derivative · entry 1 Ferrante Karen Jean · CIK 0001598502 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,073 Underlying: Common Stock · 4,073 shares Expires 2029-01-02 F1 · shares: The option award was issued to the Reporting Person, who elected to take shares in lieu of cash compensation for services as a director, pursuant to the Issuer's non-employee director compensation plan. The number of options granted was determined by dividing the cash compensation otherwise payable with respect to the quarter by the Black-Scholes value of a single option calculated as of the date of the grant. F2 · derivative.exercise_date: This option is fully vested at time of grant. Read SEC document |
| October 01, 2018 Filed Oct 3, 2018 21:14 UTC | Cogent Biosciences, Inc. UMRX · Entity 3793 | GrantStock Option (Right to Buy) · Derivative | 1,769 | $6.22 Strike: $10.37 | $11,003.18 |
DisclosureSEC source: 0001209191-18-053965 · doc4.xml · derivative · entry 1 Ferrante Karen Jean · CIK 0001598502 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,769 Underlying: Common Stock · 1,769 shares Expires 2028-10-01 F1 · shares: The option award was issued to the Reporting Person, who elected to take shares in lieu of cash compensation for services as a director, pursuant to the Issuer's non-employee director compensation plan. The number of options granted was determined by dividing the cash compensation otherwise payable with respect to the quarter by the Black-Scholes value of a single option calculated as of the date of the grant. F2 · derivative.exercise_date: This option is fully vested at time of grant. Read SEC document |
| July 26, 2018 Filed Sep 26, 2018 22:43 UTC | Cogent Biosciences, Inc. UMRX · Entity 3793 | GrantStock Option (Right to Buy) · Derivative | 1,261 | $8.72 Strike: $14.57 | $10,995.92 |
DisclosureSEC source: 0001209191-18-052360 · doc4.xml · derivative · entry 1 Ferrante Karen Jean · CIK 0001598502 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,261 Underlying: Common Stock · 1,261 shares Expires 2028-07-26 F1 · shares: The option award was issued to the Reporting Person, who elected to take shares in lieu of cash compensation for services as a director, pursuant to the Issuer's non-employee director compensation plan. The number of options granted was determined by dividing the cash compensation otherwise payable with respect to the quarter by the Black-Scholes value of a single option calculated as of the date of the grant. F2 · derivative.exercise_date: This option is fully vested at time of grant. Read SEC document |
| June 13, 2018 Filed Jun 14, 2018 14:37 UTC | PROGENICS PHARMACEUTICALS INC PGNX · Entity 148291 | GrantNon-Qualified Stock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $8.99 | $0.00 |
DisclosureSEC source: 0001562180-18-002995 · primarydocument.xml · derivative · entry 1 Ferrante Karen Jean · CIK 0001598502 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2028-06-13 F1 · derivative.exercise_date: This stock option becomes exercisable immediately on the date of grant. Read SEC document |
| May 17, 2018 Filed May 21, 2018 20:54 UTC | MACROGENICS INC MGNX · Entity 6104 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $21.34 | $0.00 |
DisclosureSEC source: 0001125345-18-000074 · wf-form4_152693607650703.xml · derivative · entry 1 Ferrante Karen Jean · CIK 0001598502 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2028-05-17 F1 · derivative.exercise_date: The option will vest and become exercisable in monthly, cumulative 1/12th increments (rounded upwards for whole shares) beginning one month from the date of grant. Read SEC document |
| June 14, 2017 Filed Jun 15, 2017 15:09 UTC | PROGENICS PHARMACEUTICALS INC PGNX · Entity 148291 | GrantNon-Qualified Stock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $6.95 | $0.00 |
DisclosureSEC source: 0001562180-17-002271 · primarydocument.xml · derivative · entry 1 Ferrante Karen Jean · CIK 0001598502 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2027-06-14 F1 · derivative.exercise_date: This stock option becomes exercisable immediately, on the date of grant. Read SEC document |
| May 18, 2017 Filed May 22, 2017 23:02 UTC | MACROGENICS INC MGNX · Entity 6104 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $19.57 | $0.00 |
DisclosureSEC source: 0001125345-17-000077 · wf-form4_149549410690686.xml · derivative · entry 1 Ferrante Karen Jean · CIK 0001598502 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2027-05-18 F1 · derivative.exercise_date: The option will vest and become exercisable in monthly, cumulative 1/12th increments (rounded upwards to whole shares) beginning one month from the date of grant. Read SEC document |
| January 24, 2017 Filed Jan 25, 2017 22:58 UTC | MACROGENICS INC MGNX · Entity 6104 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $18.52 | $0.00 |
DisclosureSEC source: 0001125345-17-000014 · wf-form4_148538510247396.xml · derivative · entry 1 Ferrante Karen Jean · CIK 0001598502 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2027-01-24 F1 · derivative.exercise_date: The option will vest 1/12th of the shares monthly, beginning on the first monthly anniversary of the grant date and will become fully exercisable 1 year from the date of grant (1/24/18). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.